

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

VOLUNTARY ANNOUNCEMENT

(1) UNUSUAL PRICE AND TRADING VOLUME MOVEMENT; AND (2) ON MARKET SHARE REPURCHASE

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company has noted the unusual price and trading volume movements of the shares of the Company (the “**Shares**”) on December 15, 2021. Having made all such enquiries with respect to the Company as is reasonable in the circumstances, the Company confirms that it is not aware of any information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). As a Contract Development and Manufacturing Organization (CDMO) offering end-to-end solutions that empower our partners to discover, develop, and manufacture biologics for the benefit of patients globally, the Company would like to emphasize that it operates in strict compliance with the applicable laws and regulations in relation to its global business operations which remain normal. As of the date hereof, the Company is not aware of any change in the regulatory regime which may result in material negative impact on the business operations. The Company will continue to strive for enabling its business partners and has full confidence in strong growth prospects.

According to the resolution passed by the shareholders of the Company at the annual general meeting of the Company held on June 16, 2021, the directors of the Company (the “**Directors**”) are generally authorized to repurchase Shares not exceeding 10% of the total number of issued Shares of the Company as at June 16, 2021 (i.e. not exceeding a total of 423,275,631 Shares) (the “**Repurchase Mandate**”). The board of Directors (the “**Board**”) hereby announces that, on December 16, 2021, it has resolved to utilize the Repurchase Mandate to repurchase Shares in the open market from time to time at an aggregate price up to US\$500 million.

Shareholders and potential investors of the Company should note that any further exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any Share repurchases or whether or not the Company will make any repurchase at all. Therefore, shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, December 16, 2021

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*